Provention Bio, Inc. (NASDAQ: PRVB)

Engel Law PLLC is investigating whether fair value to Provention shareholders will result from the proposed sale of Provention Bio, Inc. (NASDAQ: PRVB) to Sanofi for $25.00 per share.

The Firm’s investigation concerns:

(i) whether Provention’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction;
(ii) whether the $25.00 per share merger consideration adequately compensates Provention’s shareholders; and
(iii) whether all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Join this Action

Provention Bio Inc

MM slash DD slash YYYY